The Liat point of care system system has launched with four assays, including three respiratory tests and a novel test for Clostridium difficile.
Genetic analysis finds that the bird flu strain found on a Tennessee chicken farm differs from one linked to multiple deaths in China, Reuters reports.
In PNAS this week: flu susceptibility and Y chromosome variation in mice, deletion tied to epilepsy in dog breed, and more.
The tests are twice as fast as the firm's Xpert line and run on Cepheid's flagship GeneXpert system.
The White House Office of Science and Technology Policy has new guidelines for potential pandemic pathogen research, according to ScienceInsider.
The company said it expects revenues of $52 million to $53 million for the quarter, compared to analysts' average estimate of $63.1 million.
The firm also announced that it plans to expand its RAS biomarker testing collaboration with Amgen in Europe.
The bank said that although it is forecasting a 17 percent stronger flu season this year, Quidel's influenza sales are only likely to rise 10 percent.
In Science this week: genetically modified flu virus could be key to new live vaccines, and more.
The test is the first in a proposed line of assays that will run on the GeneXpress platform with run times of around 30 minutes.
Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.
University of California, San Francisco, researchers have uncovered a gene mutations that appears to make a father-son duo more efficient sleepers.
NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.
In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.